In 14 patients undergoing chronic hemodialysis, we investigated the safety and efficacy of the low molecular fragment (CY-216) in comparison to unfractionated heparin (UFH) in the prevention of clotting in the extracorporeal circuit (ECC). In this study, 168 hemodialysis sessions were undertaken with UFH in 2 bolus doses (5,437 ± 1,477 SD IU) and 231 with CY-216 in a single bolus dose [initial dose 150 anti-Xa U Institut Choay (IC)/kg]. There were no clots in the bubble trap in any UFH sessions, and 14.8% had coagulated fibers in the dialyzer. Clotting in the bubble trap was observed in 2 CY-216 sessions (0.8%) and coagulated fibers in 22.6% of the sessions. At the end of the study, the mean dose of CY-216 was 250 anti-Xa UlC/kg but a dose of 350 anti-Xa UlC/kg was needed in the 2 patients treated by recombinant human erythropoietin. Anti-Xa levels at the end of the runs were higher (0.47 ± 0.1 U/ml) in the CY-216 group than in the UFH group (0.28 ± 0.1 U/ml). There was a correlation between anti-Xa levels and efficacy in the CY-216 group. An anti-Xa activity above 0.4 U/ml was needed in order to minimize thrombus formation. Antithrombin III-protease complexes (ATM) and D dimer fibrin derivatives (D dimer) were used as thrombotic markers but they were of little value for the detection of fibrin formation in the ECC. Our findings suggest that CY-216 administered as a single bolus dose seems to be of similar effectiveness to UFH.

No abstract

No abstract

La enfermedad ateroembólica se caracteriza por la oclusión de múltiples arterias de pequeño calibre por cristales de colesterol provenientes de placas de aterosclerosis. Debido al envejecimiento de la población general y al mayor intervencionismo sobre los pacientes ateroscleróticos, es una enfermedad que en el momento actual requiere un especial interés por el aumento de su frecuencia y por la ausencia de un tratamiento eficaz.  En el presente trabajo se presenta un caso de afectación multisistémica desencadenado por tratamiento anticoagulante, y se hace una revisión de los aspectos etiopatogénicos, clínicos, analíticos, anatomopatológicos y terapéuticos de dicha enfermedad.

No abstract